New Generation Therapeutic vaccine for the Treatment of HPV infections and Cervical Dysplasia

Información del proyecto

CerviVax

Identificador del acuerdo de subvención: 698585

DOI

10.3030/698585

Proyecto cerrado

Fecha de la firma de la CE 18 Agosto 2015

Fecha de inicio 1 Septiembre 2015

Fecha de finalización 29 Febrero 2016

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

VLP THE VACCINES COMPANY
Spain

Periodic Reporting for period 1 - CerviVax (New Generation Therapeutic vaccine for the Treatment of HPV infections and Cervical Dysplasia)

Período documentado: 2015-09-01 hasta 2016-02-29

Resumen del contexto y de los objetivos generales del proyecto

VLPbio (www.vlpbio.com) is a biotechnological company applying immunotherapeutic solutions to fight and prevent human and animal diseases addressing unmet clinical needs in the main pharmaceutical markets. Our technology is based on patented and proprietary Ch-VLP platform (Chimeric Virus like Particles) derived from the Infectious Bursal Disease Virus (IBDV).

Our main product is Cervivax, an immunotherapeutic vaccine focused on the treatment of cervical dysplasia and infections caused by HPV-16 and HPV-18 (Human Papilloma Virus), which is responsible for most of the cases of cervical lesions detected all over the world. Although, there are prophylactic approaches to prevent viral infection, currently do not exist commercial therapeutic solutions to treat infections or lesions caused by the infection, other than surgery combined by chemotherapy. We position our product to cover this unmet need. We have an in vivo efficacy proof of concept of the product with excellent results, overpassing those of other therapies under development in terms of efficacy in absence of any adyuvant. The overall aim of the project is to bring CerviVax from the current status up to clinical-phase I, where we are aiming to license it to a large biotech or pharma company.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

In the first SME phase, we wanted to study the feasibility of the project. To do this, we have validated the market, we have studied in detail the competence, we have elaborated a financial plan, completed a regulatory roadmap. In relation with IP, we have up-dated FTO of CerviVax patent portfolio and defined a strategy to maintain this situation and strength it. The result of this study has been satisfactory and it was used to develop a consolidated business plan.

Once the feasibility study completed, we are able to ensure that there is a large market opportunity for CerviVax: expected quota could represent over 1,5 million patients per year. Nowadays, there are no therapeutic solutions against HPV-related diseases in the market; all products are still in development phase. The high immunogenic potential of CerviVax allows us to be confident in the competitive advantage of this vaccine among the solutions currently under development.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The result of the feasibility study together with the interest shown by some pharmaceutical companies for our products, have determined that we continuing pursuing the project idea. We are looking for funding sources to achieve our goal, which included SME instrument phase II and other sources as venture capital.

CerviVax Project